Pharmacogenomics of acetaminophen in pediatric populations: a moving target by Anne E. Krasniak et al.
REVIEW ARTICLE
published: 14 October 2014
doi: 10.3389/fgene.2014.00314
Pharmacogenomics of acetaminophen in pediatric
populations: a moving target
Anne E. Krasniak1, Gregory T. Knipp2 , Craig K. Svensson1 and Wanqing Liu 1*
1 Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA
2 Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN, USA
Edited by:
Ulrich M. Zanger, Dr. Margarete
Fischer-Bosch-Institute of Clinical
Pharmacology, Germany
Reviewed by:
LouiseWarnich, Stellenbosch
University, South Africa
Janet K. Coller, University of Adelaide,
Australia
*Correspondence:
Wanqing Liu, Department of
Medicinal Chemistry and Molecular
Pharmacology, College of Pharmacy,
Purdue University, 575 Stadium Mall
Drive, Room 224B,West Lafayette,
IN 47907, USA
e-mail: liu781@purdue.edu
Acetaminophen (APAP) iswidely used as an over-the-counter fever reducer and pain reliever.
However, the current therapeutic use of APAP is not optimal. The inter-patient variability
in both efﬁcacy and toxicity limits the use of this drug. This is particularly an issue in
pediatric populations, where tools for predicting drug efﬁcacy and developmental toxicity
are not well established. Variability in toxicity between age groups may be accounted for
by differences in metabolism, transport, and the genetics behind those differences.While
pharmacogenomics has been revolutionizing the paradigm of pharmacotherapy for many
drugs, its application in pediatric populations faces signiﬁcant challenges given the dynamic
ontogenic changes in cellular and systems physiology. In this review we focused on
the ontogenesis of the regulatory pathways involved in the disposition of APAP and on
the variability between pediatric, adolescent, and adult patients. We also summarize
important polymorphisms of the pharmacogenes associated with APAP metabolism.
Pharmacogenetic studies in pediatric APAP treatment are also reviewed.We conclude that
while a consensus in pharmacogenetic management of APAP in pediatric populations has
not been achieved, a systems biology based strategy for comprehensively understanding
the ontogenic regulatory pathway as well as the interaction between age and genetic
variations are particularly necessary in order to address this question.
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INTRODUCTION
It has been over half a century since acetaminophen (APAP), or
paracetamol, was approved by the United States Food and Drug
Administration (FDA) to be used as an analgesic and antipyretic.
APAP is commonly used to mitigate mild pain or headache symp-
toms and is available over the counter in the United States. It is also
frequently used in combination with more powerful pain relievers
such as hydrocodone or oxycodone via prescription drug products.
Despite its wide use, optimal dosing to achieve efﬁcacy and min-
imize toxicity remains problematic. Thus, the unregulated access
and non-compliant use of APAP leading to an overdose is one of
the leading causes of drug induced liver injury (Food and Drug
Administration, 2014). Since such liver injury is generally progres-
sive, sometimes leading to the need for liver transplantation, the
optimal goal is prevention of overdose and subsequent toxicity by
increasing awareness. Based on the prevalence of hepatic injury,
the FDA recently lowered the maximum daily dose of APAP from
4 g/day to 3 g/day, and has also stated that doses over 325 mg
may cause liver toxicity (Food and Drug Administration, 2014).
In addition to the dosing change, it is of high interest to identify
patients that are most and least susceptible to liver damage from
APAP for prophylactic purposes.
APAP is a commonly used fever reducer in pediatric pop-
ulations. Although numerous dosage forms have been devel-
oped for the pediatric population, the current dosage recom-
mendations for APAP in children still largely rely on body
weight. However, pediatric patients are not simply small adults.
They often require vastly different treatment because of their
dynamic physiology that affects the pharmacokinetics (PK),
including absorption, distribution, metabolism, and excretion
(ADME) of many drugs. Differences in APAP PK, pharma-
codynamics (PD), toxicity proﬁle and efﬁcacy between indi-
viduals and populations have been widely noted (Ward et al.,
2001; Pineiro-Carrerro and Pineiro, 2004; Zuppa et al., 2011;
Leonis et al., 2013). While pharmacogenetic and pharmacoge-
nomic approaches have been applied to understand the inter-
patient difference in pharmacological phenotypes of many drugs,
studies in these areas addressing the variability of APAP PK/PD
are still limited. While the complex PK process of APAP might be
a signiﬁcant hurdle for this, it is particularly difﬁcult to apply
these approaches in pediatric populations due to the dynamic
physiology, sample availability, difﬁculties in monitoring phe-
notypes, etc. The ontogenesis of drug ADME pathways plays
an important role in determining a patient’s response to the
drug. Thus, in deploying APAP as a therapeutic option, one
must account for both age-dependent differences in the PK/PD
of APAP and the inter-patient variability within the pediatric
population itself. Both sources of variability will contribute to
the individual susceptibility to toxicity from this widely used
agent.
Here we review the major clinical outcome variability for APAP
observed between pediatric and adult patients, as well as among
children of different ages. We also summarize the progress in
understanding the role of genetic alleles and age-related gene
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expression as it pertains to the phenotypic variability between
patients. Lastly, we also highlight the challenges as well as new
opportunities in APAP pharmacogenomic research.
INTER-PATIENT VARIABILITY IN PEDIATRIC APAP
PHARMACOLOGY
TOXICITY AND EFFICACY
Acetaminophen is generally well tolerated, making it an attrac-
tive choice for the treatment of fever and pain in the pediatric
population. Hepatotoxicity is the greatest concern associated with
APAP treatment. A 1981 study showed that younger patients had
less hepatotoxicity when exposed to the same levels of APAP
acutely as older children and adults (Rumack et al., 1981). How-
ever, the pediatric acute liver failure study group has found
that in chronic exposure to APAP (in contrast to a single
toxic dose), younger patients (median age, 3.5 years) expe-
rienced a greater level of hepatotoxicity comparative to older
adolescent patients (median age 15.2 years) who were more
likely to experience hepatotoxicity from a single toxic dose
(Rumack et al., 1981).
The reason underlying this age difference in toxicity remains
incompletely understood. It has been noted that younger chil-
dren may be less susceptible to APAP-induced hepatotoxicity
because of increased glutathione stores or metabolism dif-
ferences as a result of genetic variability (Pineiro-Carrerro
and Pineiro, 2004). Glutathione synthetase deﬁciency leads to
elevated N-acetyl-p-benzoquinone imine (NAPQI) and increased
hepatotoxicity (Dahlin and Nelson, 1982) (See Figure 1 for
the pathway). The toxicity of APAP is linked closely to its
metabolism in the body. A ceiling dose of APAP for chil-
dren has not been established because therapeutic doses that
have been administered to children have caused toxicity in
some cases. This may be because conditions vary between
children, particularly pharmacogenetic differences, drug inter-
actions, current medical disorders, or malnutrition. Nutri-
tional deﬁciencies and drug-drug interactions are most likely
to cause differences in metabolism and toxicity at normal
doses (Ward et al., 2001). Ethnicity also plays a large role in
the frequency of functional polymorphisms in pharmacogenes,
and the appearance of these pharmacogenes can vary greatly
between different ethnic populations (Suarez-Kurtz et al., 2014).
These polymorphisms may also account for variability in APAP
metabolism.
Besides hepatotoxicity, other APAP side effects have also been
observed in children. A cross-sectional study of children 2–6 years
of age concluded that frequentAPAPuse in these patientswas asso-
ciated with the formation of a wheeze or asthma (Nguyen et al.,
2013). Several other studies were also reviewed and revealed that
children who received APAP in the ﬁrst year of life were asso-
ciated with a signiﬁcant increase in risk for wheezing later in
life. Patients that received APAP regularly for fever had higher
risk for more severe, concurrent asthma symptoms (Nguyen
FIGURE 1 | Pathways and enzymes involved in the metabolism of acetaminophen (APAP). Note: APAP-Gluc, APAP-glucuronide; APAP-Cys,
3-cysteinyl-APAP.
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et al., 2013). In another study, a clear dose-response relationship
was identiﬁed between daily use of APAP and increased asthma
morbidity (Henderson and Shaheen, 2013). It is unclear if this
represents an effect of APAP itself or if the factors precipitating
the use of APAP (e.g., upper respiratory tract infections) presage
the development of airway disease. Other adverse reactions asso-
ciated with APAP include Stevens-Johnson Syndrome, and toxic
epidermal necrolysis (Kim et al., 2014).
While there have been many proposed mechanisms, the exact
mechanism of action of APAP remains unclear. The efﬁcacy of
APAP is dose-dependent, which is affected by the PK in the
different age groups. This was demonstrated in a study which
noted that rescue morphine was used more frequently in patients
with lower APAP concentrations (Anderson et al., 1996). Fur-
thermore, it was noted in the same study that children with
APAP concentrations about 10 mg/L had a better analgesic
response than those with an APAP concentration below 10 mg/L
(Anderson et al., 1996).
Differences in APAP efﬁcacy among pediatric and adult popu-
lationswere also observed. In one study of children ages 10months
to 4 years, it was found that APAP lowered the fevers of some chil-
dren with febrile seizure and a temperature above 38.5oC more
effectively than it lowered the fevers of other children (Van Esch
et al., 1995). Analysis of the use of APAP to treat children and
adolescent patients (ages 4–18) with migraines determined that
headaches were reduced by a mean of 1.5 points on a pain scale
with the use of APAP after migraine occurrence (Damen et al.,
2005). A separate investigation on adults with migraines, APAP
was used in combinationwith caffeine to treatmigraine headaches.
That study indicated that migraine headache pain was relieved by
1 point on a pain scale (Pini et al., 2012). Another study in adults
aged 19–64 with migraine headaches found that APAP reduced
pain by 0.6 points on a pain scale (Pini et al., 2008). While pain
scales are very subjective measures of efﬁcacy, they indicate that
there might be some difference in the efﬁcacy of APAP between
children and adults.
APAP PHARMACOKINETICS IN CHILDREN
As has been observed with many other drugs, the variabil-
ity in APAP PK varies with age from birth to adulthood. In
a study performed on 75 subjects (3 neonates, 25 infants,
25 children, and 22 adolescents), a PK model was developed
from data following intravenous APAP administration (Zuppa
et al., 2011). The clearance (L/hr) of APAP increased from
2.02 L/hr at 1 month of age to 4.09 L/hr at 1 year of age
to 14.27 L/hr at 16 years of age (based on our own analy-
ses on the published mean values with a Spearman correlation,
there is a signiﬁcant correlation between age and APAP clear-
ance, p < 0.0001), while the central volume of distribution
remained constant at 0.23 L/kg for all ages. Also, the AUC val-
ues were 60 to 90% higher than those measured in children
and adolescents in the study (Zuppa et al., 2011). Although it
is unclear whether this is statistically signiﬁcant because of the
small number of neonates in the study (n ≤ 2), the data indicate
a possibly large variability in the elimination of APAP in the pedi-
atric population, especially between neonates and older children
(Zuppa et al., 2011).
APAP metabolism and excretion processes are very complex
with both Phase I (oxidation) and Phase II metabolism path-
ways (glucuronidation, sulfation, and glutathione conjugation)
involved (Figure 1). In the aforementioned study and illustrated
in Figure 2, the fraction of APAP-sulfate excreted is fairly similar
across age groups, indicating that APAP sulfation is likely constant
among all ages (Zuppa et al., 2011). In contrast, the increased
fraction of 3-cysteinyl-APAP recovered along with age suggests
that there might be an increase in activity of either oxidative
or glutathione S-transferase (GST) enzyme isoform activity from
neonate to adolescence populations. As expected, the glucuronida-
tion of APAP increased in older children, with a particularly
dramatic elevation of over 20-fold observed between the neonate
to the infant stage, albeit the statistical signiﬁcance remains unclear
given the small number of neonates in this study. This assessment
must be qualiﬁed by the recognition that total urinary recov-
ery also varied with age (Zuppa et al., 2011). Other investigators
have demonstrated that glucuronide/sulfate ratios are 0.12 in pre-
mature neonates ( < 32 weeks), 0.28 in neonates 32–36 weeks
post-conception, 0.34 in neonates 0–2 days old, 0.75 in children
3–9 years, and 1.8 in adults (Miller et al., 1976; van der Marel et al.,
2003). Taken together, these data indicate an increased role of glu-
curonidation in the metabolism of APAP during maturation to
adolescence. The total fraction of APAP metabolites recovered in
the urine increased from 48.7 for neonates to 71.1 for infants, and
92.6 for adolescents (Zuppa et al., 2011).
MOLECULAR BASIS OF INTER-PATIENT DIFFERENCES
ACETAMINOPHEN ADME
APAP is absorbed almost completely in the duodenum (McGill
and Jaeschke, 2013). It is eliminated in the liver, where the
drug is predominantly conjugated to glucuronic acid or sulfate
(Figure 1). After glucuronidation, the metabolites are excreted
in the urine. Glucuronidation is carried out by several UDP-
glucuronosyl transferases (UGTs) with the enzymes UGT1A1 and
UGT1A6 identiﬁed as the most important (Miller et al., 1976).
APAP is also largely metabolized by sulfation, which is cat-
alyzed by sulfotransferase (SULT) enzymes (Ward et al., 2001).
While sulfation is relatively less understood than glucuronida-
tion, it is known that SULT1A1 is primarily responsible for
the sulfation of APAP (Rowden et al., 2005). After therapeutic
doses, a small portion of a dose is converted into a reactive
metabolite, NAPQI , by the cytochrome P450 (CYP) enzymes,
primarily CYP2E1, CYP1A2, and CYP3A4, but also several others
(Rowden et al., 2005). In normal dosing, the glutathione-S-
transferase (GST) enzymes convert NAPQI into acetylamino-2-
hydroxyphenyl-glutathione (Zuppa et al., 2011). It is when the
GST enzymes are overwhelmed and liver glutathione is depleted
that liver toxicity due to APAP occurs (McGill and Jaeschke,
2013). The CYP activities, particularly 1A2, 2E1, and 3A4, play
a critical role in APAP-induced liver injury, because they produce
the toxic metabolite (Figure 1). This has been shown in many
studies (Raucy et al., 1989; Lee et al., 1996; Cheung et al., 2005;
Gonzalez, 2005). One particular study was performed on three
different types of mice: wild-type, cyp2e1-null, and CYP2E1-
humanized mice. When the mice were given 400 mg/kg of
APAP, moderate liver necrosis was detected in the wild-type mice.
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FIGURE 2 | Differing amounts of the metabolites of acetaminophen that are excreted into the urine across different age groups. [Data were adapted
from Zuppa et al. (2011) with permission]. Shown here is the steady state urinary data presented as percent fractional excretion (y-axis).
However, it was not detected in the cyp2e1-null mice. The same
dose given to the CYP2E1-humanized mice resulted in severe
liver necrosis (Cheung et al., 2005). In another study investigat-
ing the role of CYP1A2 in hepatotoxicity, it was found that at
doses over 600 mg/kg, cyp2e1-null mice experienced hepatotox-
icity. This indicates that CYP1A2 and other CYP enzymes are
also partially responsible for conversion of APAP to NAPQI (Lee
et al., 1996). However, CYP2E1 had a lower Km than CYP1A2
(Snawder et al., 1994; Hazai et al., 2002). In a different study, it was
found that inhibition of both CYP2E1 and CYP2A6 signiﬁcantly
decreased the formation of NAPQI (Gonzalez, 2005), suggesting
multiple CYPs are involved in the development of APAP hep-
atotoxicity. Inhibition of CYP1A2 and CYP3A4 did not reduce
NAPQI formation (Gonzalez, 2005). These studies broadly suggest
that there are several CYPs involved in APAP induced hepato-
toxicity (Raucy et al., 1989; Lee et al., 1996; Cheung et al., 2005;
Gonzalez, 2005).
AGE-DEPENDENT CHANGES IN THE APAP METABOLISM PATHWAYS
Among pediatric populations, one important factor inﬂuencing
inter-patient difference in response to APAP is the ontogeny of
various metabolic enzymes. The expression of cytochrome P450
enzymes changes during the development from child to adult.
While several P450 enzymes play a role in metabolizing APAP, one
particularly relevant enzyme in humans regarding APAP-induced
hepatotoxicity is CYP2E1 (Johnsrud et al., 2003). In a develop-
mental protein expression pattern study, human hepatic CYP2E1
expression patterns were determined by Western blot analysis of
238 different human liver samples (Vieira et al., 1996). In these
238 livers, it was found that neonatal CYP2E1 levels were lower
than infants aged 31–90 days. The infant CYP2E1 levels were
lower than levels found in older children and adults. CYP2E1
protein levels in third trimester fetuses were only 10% of the
levels from samples of infants older than 90 days. There was a
large variation (80-fold between neonatal samples while only a
4-fold difference was seen within other age groups (Vieira et al.,
1996). In another study, postnatal data indicated that infants
younger than 90 days old had decreased clearance of CYP2E1
substrates in comparison to older children and adults (Cheung
et al., 2005). This would lead to a decreased formation of the
toxic metabolite of APAP,which potentially allows younger infants
to have a decreased risk of hepatotoxicity. Also, it was found
that increased postnatal age and ethnicity, but not gender, were
signiﬁcant factors that affected CYP2E1 developmental expres-
sion (McGill and Jaeschke, 2013). Differences in developmental
expression were also observed between postnatal infants younger
than 90 days and older infants (91 days-18 years of age) and
adults (over 18 years of age; Vieira et al., 1996). Other studies
in addition to those stated here have also consistently shown that
CYP2E1 levels are undetectable in fetal liver, but rise after birth and
with increasing age (Court et al., 2001; Lejus et al., 2002). These
enzyme expression levels undoubtedly affect APAP metabolism
in different age groups. In addition to age, ethnicity may also
affect CYP2E1 gene expression. For example, higher CYP2E1 pro-
tein content was found in Northern European-Americans and
Hispanic-Americans than in African-Americans (Johnsrud et al.,
2003). All of these differences could be linked to variability in
APAP metabolism.
Differences inAPAPglucuronidationbyUGTenzymesbetween
individuals can also change the level of susceptibility to APAP
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toxicity in humans (Strassburg et al., 2002). The hepatic UGT
expression level changes from birth to adult age. UGT1A1 and
1A6 develop differently in the pediatric liver. In a study on
UGT expression at different ages, it was found that UGT1A and
UGT2B gene expression was absent in fetal liver at 20 weeks
gestation, while UGT1A1 and UGT1A6 were present in all
samples of pediatric and adult livers, which demonstrates
that de novo expression of UGT genes does not occur after
6 months (Strassburg et al., 2002). UGT1A9 and UGT2B4 were
identiﬁed at signiﬁcantly lower expression in pediatric liv-
ers, and regulation of UGT1A9 expression continues beyond
2 years of age and may continue to affect drug metabolism
(Strassburg et al., 2002). In the same study, it was determined
that age dependent changes did not occur after 6 months of age
between UGT1A1 and UGT1A6 expression at either the tran-
scription or the protein level. UGT genes are expressed after the
fetal/early infant period and the differential upregulation of UGT
gene expression occurs after 6 months until 24 months of age
(Strassburg et al., 2002).
In contrast, studies indicate that human hepatic SULT1A1 is
expressed in comparable levels in both fetal and postnatal human
livers (Duanmu et al., 2006). The increasing UGT expression in
the face of stable SULT expression may be particularly consis-
tentwith the aforementioned increasing glucuronide/sulfate ratios
from premature neonates to adults (McGill and Jaeschke, 2013).
POLYMORPHISMS AFFECTING APAP METABOLISM
Besides the ontogenic effect, genetic polymorphisms are poten-
tially an important factor leading to differential toxic responses
in APAP metabolism in humans. A CYP2E1 promoter RsaI
restriction fragment length polymorphism (RFLP; rs2031920)
was associated with half-life of APAP in human subjects in a
small cohort study (Ueshima et al., 1996). In the coding region,
however, CYP2E1 polymorphisms are rare, and most of them
do not seem to have any direct effect on the enzyme activity
(Hu et al., 1997). Three non-synonymous polymorphisms that
affect coding sequences have been recently deﬁned. One of these
polymorphisms, R76H or CYP2E1∗2 (rs72559710), demonstrates
decreased catalytic activity. This polymorphism has been identi-
ﬁed at a low frequency in Chinese populations, but is not observed
in any other ethnic groups (Hu et al., 1997). In vitro study sug-
gested that CYP2E1∗2 decreases protein expression and catalytic
activity of the enzyme (Hu et al., 1997). The CYP2E1∗1D (a repeat
variant) polymorphism leads to increased CYP metabolic activ-
ity and likely explains the differences in ethnicity in CYP2E1
developmental expression (Cheung et al., 2005). Recent expression
quantitative traits loci (eQTL) mapping in human liver tissue has
suggested that a single nucleotide polymorphism (SNP) rs4512750
located at the CYP2E1 3′ﬂanking region is strongly (p < 10−10)
associated with CYP2E1 mRNA expression in the liver (Schadt
et al., 2008). Our in silico analysis further found that this poly-
morphism is in strong linkage disequilibrium (LD) with two
polymorphisms (rs2480256 and rs2480257) located at theCYP2E1
3′-UTR (untranslated region) which potentially alter microRNA
targeting (Wei et al., 2012). However, no study was conducted
thus far in testing the association between these polymorphisms
and APAP metabolism or toxicity.
Regarding CYP1A2, numerous genetic polymorphisms have
been identiﬁed, but none of them are currently tested for their
relationship with APAP metabolism. CYP3A4 is another major
P450 enzymes involved in APAP metabolism. Although sev-
eral polymorphisms have been observed in the gene region
that involved in metabolism of many drugs, no indisputable
evidence has been obtained thus far to demonstrate a linkage
between these polymorphisms and CYP3A4 activity. On the other
hand, CYP3A4 was more inducible with a few transcription fac-
tors involved such as pregnane X receptor (PXR), hepatocyte
nuclear factor 3-alpha (FoxA2) and peroxisome proliferator-
activated receptor-α (PPARA; Lamba et al., 2008; Klein et al.,
2012). Previous studies suggested that polymorphisms in these
factors may indirectly affect the variability in CYP3A4 transcrip-
tion, e.g., PPARA rs4253728 (Klein et al., 2012), PXR -6944CC
(rs2472677), -6513CC (rs6438546), and -4356TT (rs13059232)
genotypes (Lamba et al., 2008), as well as FoxA2 rs1212275
and -415(CGG)n polymorphisms (Lamba et al., 2010). Unfor-
tunately, the relationship between these polymorphisms and
APAP metabolism remains unexplored. Since higher inducibil-
ity of CYP3A4 increases production of toxic metabolite and
may increase the likelihood of APAP-induced hepatotoxicity, the
importance of these polymorphisms in APAP pharmacogenetics
should be investigated. Additionally, CYP3A7 is detected at a very
high level in human embryonic, fetal, and newborn livers, but is
much lower in adult livers (De Wildt et al., 1999). In contrast with
these genes, CYP3A5 has similar activity as CYP3A4 and alleles
clearly inﬂuencing CYP3A5 activity have been identiﬁed previ-
ously, e.g., CYP3A5∗3 (rs776746) and CYP3A5∗7 (rs41303343;
Hustert et al., 2001; Kuehl et al., 2001). In a recent study, it
was demonstrated that individuals with the A allele (CYP3A5∗1)
of the CYP3A5 rs776746 polymorphism have enhanced forma-
tion of NAPQI from APAP compared to individuals with the
G allele (CYP3A5∗3), who lacked CYP3A5 activity (Court et al.,
2014).
Signiﬁcant work has sought to characterize the effect of poly-
morphisms in UGT genes on APAP. For example, a potential
association between SNPs rs10929303, rs1042640, and rs8330
located in the UGT1A-3′UTR region and APAP glucuronida-
tion variability was observed in human liver microsomes (Court
et al., 2013). These SNPs have greater potential to change dis-
position of APAP, which is glucuronidated by multiple UGT1A
isoforms, as the 3′-UTR is shared by all UGT1A genes (Court
et al., 2013). Of the three UGT1A-3′UTR SNPs stated above exam-
ined in this study, rs8330 was the most signiﬁcant SNP related
to APAP glucuronidation phenotype at all three concentrations
tested in human liver bank samples (0.1, 2, and 40 mM). The
rs8330 SNP also demonstrated decreased risk of hepatotoxicity
due to APAP glucuronidation. The rs8330 minor allele frequency
was most prevalent in African (0.39) and Yoruba (0.50) and least
prevalent in white America (0.16) and Asian (0.13; Court et al.,
2013). Polymorphisms in UGT1A6 were also linked to APAP
metabolism variability. It was determined that threeUGT1A6 cod-
ing region SNPs [S7A (rs6759892), T181A (rs2070959), andR184S
(rs1105879)] had a quantiﬁable effect on glucuronidation (Krish-
naswamy et al., 2005a,b). Compared to the UGT1A6∗1 (haplotype
of multiple alleles), the UGT1A6∗2 (haplotype of multiple alleles)
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allozyme showed two-fold higher intrinsic clearance values. These
SNPs are thought to account for 15 to 20% of the 13-fold vari-
ability of UGT glucuronidation (Krishnaswamy et al., 2005a,b).
The importance of these alleles in APAP pharmacogenetics needs
further validation. It should be noted that UGT1A genes has a
unique genomic organization where there are a tandem array of
exons 1 followed by common exons 2–5. Linkage disequilibrium
across the entire UGT1A locus is generally high (Liu et al., 2005;
Maitland et al., 2006). Given the multiple UGTs involved in APAP
metabolism, pharmacogenetic research should focus on a locus-
wide rather than individual gene (exon 1) level. Our group has
recently performed a comprehensive analysis of UGT expression
quantitative trait loci (eQTLs) in a large set of liver samples, with a
number of signiﬁcant eQTLs identiﬁed (Liu et al., 2014). The rela-
tionship between these eQTLs and APAP metabolism or toxicity
should be considered in future research.
It is also noteworthy that there are several UGT1A splic-
ing isoforms (UGT1A_i2) that may repress APAP glucuronida-
tion (Court et al., 2013). Co-expression of the UGT1A6_i2
inhibits glucuronidation of APAP by 90%. In the same study,
UGT1A1_i2 inhibited UGT1A1_i1 regulated glucuronidation by
nearly 30% (Court et al., 2013). Either of these isoform vari-
ants expressed in an individual would be expected to lead to
decreased APAP glucuronidation and increased incidence of
APAP-induced liver toxicity. However, whether the expression
patterns of these isoforms vary among pediatric populations
and consequently contribute to inter-patient variability in APAP
metabolism or toxicity remains unknown and requires further
research.
Polymorphisms in SULT and GST genes are not as well
established, and therefore the existence and effect of such poly-
morphisms on APAP metabolism are not well known. However,
there have been a few studies regarding the effect of such polymor-
phisms, e.g., SULT1A1∗2 (rs9282861) did demonstrate a decreased
enzymatic activity compared to ∗1 (reference haplotype) and ∗3
(rs1801030), which may indicate a potential for increased risk
of hepatotoxicity (Nagar et al., 2006). Copy number variants in
SULT1A1 with functional signiﬁcance have also recently been
reported (Hebbring et al., 2007), but their relationship with APAP
metabolism remains unclear. Regarding GSTP1, two polymor-
phisms (rs1695 and rs1138272) have been described. Both are
in the substrate binding site and result in amino acid substi-
tutions (Ile105Val and Ala114Val, respectively; Dragovic et al.,
2014). These polymorphisms have demonstrated small effects on
several substrates’ GSTP1 kinetics, and may not be of any phar-
macological or physiological signiﬁcance (Dragovic et al., 2014).
However, a recent study demonstrated that GSTP1 polymor-
phism signiﬁcantly modiﬁed risk of wheeze in children with age
5 years who had prenatal exposure to APAP (Perzanowski et al.,
2010), while an another study of APAP use versus childhood
asthma incidence, maternal GSTT1 and GSTM1 but not GSTP1
genotypes were found to modify the risk of asthma incidence
(Shaheen et al., 2010).
It is worth mentioning that the majority of these polymor-
phisms have signiﬁcant ethnic difference in their allele fre-
quency according to the HapMap data. Previous studies have
demonstrated signiﬁcant difference in APAP metabolism and
hepatotoxicity between ethnicities, e.g., metabolic activation of
APAP is signiﬁcantly lower in Africans than Caucasians (Critchley
et al., 1986), while the rate of APAP-induced hepatotoxicity was
observed to be low in a large, multi-ethnic Asian population, as
compared with reported data in western countries (Marzilawati
et al., 2012). Another study also showed that Chinese subjects may
possess more rapid APAP absorption, as well as different pro-
ﬁle of metabolism via different pathways compared to Caucasians
(Critchley et al., 2005).Whether these polymorphisms affectAPAP
metabolism or toxicity and further account for the ethnic differ-
ence has yet to be tested and remains an open question for further
investigation.
CONCLUSION
Signiﬁcant inter-patient differences in both APAP PK and toxicity
proﬁles have been observed between adults and children as well
as between pediatric populations. This variability is attributed to
both the ontogenic expression of the APAP metabolism pathway
and genetic variations and may be the reason behind variability
in toxicities in different age groups. However, a comprehensive
evaluation has not been achieved for the ontogeny of all involved
genes. The interaction between genetic variants and age-related
gene expression has not been determined, which largely limits the
pharmacogenomic research for APAP-related clinical outcomes.
As a consequence, the development of reliable biomarkers that will
aid in the clinicalmanagement of APAP toxicity across all agesmay
bemore pressing for identifying pediatric hepatotoxicity, although
such indicators have yet to be identiﬁed.
FUTURE RESEARCH
Further research is required in order to identify causes for disparity
in APAP metabolism and the resultant induced toxicities amongst
pediatric populations and adults. To this end, given the complex-
ity of pediatric APAP pharmacology, a systems based approach is
particularly necessary to combine comprehensive investigation of
gene ontogeny, pathway- or genome-wide genotyping as well as
uncovering gene-age based interactions. As more “omics”-based
tools are currently available, it is important to integrate data in
multiple levels (e.g., metabolomic studies of APAP would give
more detailed information about multiple APAP metabolites and
how they change from birth to adulthood). Moreover, integrated
genomic (genotype) and transcriptomic/proteomic (expression)
data such as eQTL analysis could lead to identifying age-dependent
genetic alleles determining mRNA and protein expression differ-
ences during human development. For example, high-throughput
sequencing represents an efﬁcient strategy to identify rare genetic
variants that may confer a larger effect on pharmacogenomic phe-
notypes. Although the functionality of rare variants may not be
easily determined, it has been suggested that the entire spectrumof
variants including both common and rare one should be included
in routine pharmacogenomic research (Drögemöller et al., 2014).
In addition to human studies, cell line-based in vitro models and
animal models could be also useful for further characterizing the
mechanism underlying APAP-induced hepatoxicity. For instance,
it has been demonstrated that 3D organotypic culture of the
human hepatoma HepRG cells is capable of maintaining hepatic
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function and is more sensitive to APAP-induced toxicity as com-
pared to the conventional 2D cell culture (Gunness et al., 2013).
Sequencing study in two independent cohorts of mouse popu-
lations also linked CD44 expression to increased APAP-induced
hepatotoxicity (Harrill et al., 2009). Furthermore, the pig has been
reviewed tobe apromisingmodel as the drugmetabolismand toxi-
cities in pigs are similar to those of humans (Puccinelli et al., 2011).
The great power of these approaches and models in pharma-
cogenomic research has been increasingly demonstrated recently,
and thus offer great hope for increasing our knowledge regarding
ontogenic APAP metabolism and toxicokinetics.
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